World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
39936
World Ranking
13885
National Ranking
448

Overview

Valérie Boige is affiliated with the Institut Gustave Roussy in France and has an extensive research portfolio primarily in the field of Medicine, with a focus on Oncology. Their scholarly output includes significant contributions to the study of cancer treatments, particularly colorectal cancer, hepatocellular carcinoma, pancreatic and hepatic oncology, as well as gastric cancer management.

Their work covers various subfields such as oncology, surgery, pulmonary and respiratory medicine, hepatology, and cancer research. Boige's research topics emphasize colorectal cancer treatments and studies, hepatocellular carcinoma treatment and prognosis, pancreatic and hepatic oncology research, cancer genomics and diagnostics, colorectal and anal carcinomas, gastric cancer management and outcomes, and cancer treatment and pharmacology.

Boige has published notable papers including:

  • Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial, 2021, The Lancet Oncology
  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial, 2023, The Lancet Oncology
  • Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma, 2024, Annals of Oncology
  • Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study, 2020, The Lancet Oncology
  • Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial, 2020, Journal of Clinical Oncology

Frequent collaborators in Boige's research include:

  • Antoine Hollebecque
  • Michel Ducreux
  • Cristina Smolenschi
  • Alice Boilève
  • David Malka

The venues where Boige's research is regularly published demonstrate a pattern of engagement with well-established oncology and cancer research journals. Key publication venues include:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • European Journal of Cancer
  • Cancers
  • Annals of Surgical Oncology

Boige's research contributions integrate clinical trials, chemotherapy protocols, immunotherapy, surgical oncology, and diagnostic advances. This body of work addresses therapeutic strategies for several gastrointestinal cancers, underpinning treatment advances in locally advanced rectal cancer, advanced gastric cancer, hepatocellular carcinoma, and colorectal peritoneal metastases.

Best Publications

  • The consensus molecular subtypes of colorectal cancer

    Justin Guinney;Rodrigo Dienstmann;Rodrigo Dienstmann;Xingwu Wang;Xingwu Wang;Aurélien De Reyniès

  • KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

    Astrid Lièvre;Jean-Baptiste Bachet;Delphine Le Corre;Valérie Boige

  • Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial

    Marc Ychou;Valérie Boige;Jean-Pierre Pignon;Thierry Conroy

  • KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

    Astrid Lièvre;Jean-Baptiste Bachet;Valérie Boige;Anne Cayre

  • Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value

    Laetitia Marisa;Aurélien de Reyniès;Alex Duval;Alex Duval;Janick Selves

  • Immunogenic death of colon cancer cells treated with oxaliplatin.

    A. Tesniere;F. Schlemmer;F. Schlemmer;F. Schlemmer;V. Boige;O. Kepp;O. Kepp;O. Kepp

  • Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

    Pierre Laurent-Puig;Anne Cayre;Gilles Manceau;Emmanuel Buc

  • Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

    Thierry Conroy;Jean-François Bosset;Pierre-Luc Etienne;Emmanuel Rio

  • Cutaneous side-effects of kinase inhibitors and blocking antibodies

    Caroline Robert;Jean-Charles Soria;Alain Spatz;Axel Le Cesne

  • Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

    Josep M. Llovet;Thomas Decaens;Jean-Luc Raoul;Eveline Boucher

  • Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901

    Christophe Mariette;Laetitia Dahan;Françoise Mornex;Emilie Maillard

  • Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.

    D. Elias;F. Blot;A. El Otmany;S. Antoun

  • Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year.

    Thierry de Baere;Dominique Elias;Clarisse Dromain;Mostafa Gamal El Din

  • Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

    Sophie Gourgou-Bourgade;Caroline Bascoul-Mollevi;Françoise Desseigne;Marc Ychou

  • Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging.

    Clarisse Dromain;Thierry de Baere;Jean Lumbroso;Hubert Caillet

  • Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

    Erika Vacchelli;Yuting Ma;Elisa E. Baracco;Antonella Sistigu

  • Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

    Thierry Conroy;Marie-Pierre Galais;Jean-Luc Raoul;Olivier Bouché

  • Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation.

    Thierry de Baère;Jean Palussière;Anne Aupérin;Antoine Hakime

  • Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up.

    Clarisse Dromain;Thierry de Baere;Dominique Elias;Viseth Kuoch

  • Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases

    T. de Baère;A. Aupérin;F. Deschamps;P. Chevallier

Frequent Co-Authors

Michel Ducreux
Michel Ducreux Institut Gustave Roussy
David Malka
David Malka Institut Mutualiste Montsouris
Dominique Elias
Dominique Elias Institut Gustave Roussy
Pierre Laurent-Puig
Pierre Laurent-Puig Université Paris Cité
Olivier Bouché
Olivier Bouché CHU de Reims
Julien Taieb
Julien Taieb Université Paris Cité
Thierry de Baere
Thierry de Baere Institut Gustave Roussy
François Ghiringhelli
François Ghiringhelli Centre Georges François Leclerc
Philippe Rougier
Philippe Rougier University of Nantes
Jean-Luc Raoul
Jean-Luc Raoul Institut de Cancérologie de l'Ouest (ICO)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in Medicine doesn't always mean attending traditional medical school. There are many flexible, online programs that align well with a variety of healthcare goals.

For those pursuing advanced nursing roles, asn to fnp programs allow registered nurses to bridge to a family nurse practitioner specialty. If your interests are more focused on nutrition and wellness, earning an online degree in nutrition can open opportunities in clinical, community, or corporate settings.

For aspiring healthcare leaders, the best mha programs offer online pathways to earn a Master of Health Administration, preparing you for management in hospitals and healthcare organizations. Meanwhile, practicing RNs with limited time for on-site requirements can complete their BSN via rn to bsn programs without clinicals.

Each of these online degrees expands your healthcare career options and provides flexibility to balance work, study, and personal responsibilities.

Best Scientists Citing Valérie Boige

Trending Scientists

Recently Published Articles